Anti-inflammatory effect of pirfenidone in the bleomycin- hamster model of lung inflammation

Inflammation

Volumn 24, Issue 5, 2000, Pages 477-491

  Iyer, Swarnalatha N ^a   Hyde, Dallas M ^a   Giri, Shri N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; HAMSTER; INFLAMMATORY CELL; LUNG LAVAGE; LYMPHOCYTE; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; PNEUMONIA;

ADMINISTRATION, ORAL; ANIMAL FEED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CRICETINAE; INFLAMMATION; MACROPHAGES, ALVEOLAR; MALE; MESOCRICETUS; NEUTROPHIL INFILTRATION; PULMONARY FIBROSIS; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; CRICETINAE;

EID: 0033923129     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007068313370     Document Type: Article

References (53)

1. 1. RENNARD, S. I., P. B. BITTERMAN, AND R. G. CRYSTAL. 1984. Current concepts of the pathogenesis of Fibrosis: Lessons from Pulmonary fibrosis. Prog. Clin. Biol. Res. 154:359-377.
2. 2. KUMAR, R. K. and T. W. J. LYKE. 1995. Messages and Handshakes: Cellular interaction in pulmonary fibrosis. Pathol. 27:18-26.
3. 3. RYAN, G. B. and G. MAJNO. 1977. Chronic Inflammation, Inflammation, The Upjohn Co, 58-59.
4. 4. THRALL, R. S. and P. J. SCALISE. 1995. Bleomycin. In: Pulmonary fibrosis. S. M. Phan, R. S. Thrall, editors. Marcel Dekker, Inc., New York. 80:241-242.
5. 5. LAZO, J. S., D. G. HYOTT, S. M. SEBTI, and B. R. PITT. (1990). Bleomycin: A pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol. Ther. 47:347-358.
6. 6. WEINBERGER, S. E., J. A. KELMAN, N. A. ELSON, R. C. J. YOUNG, H. Y. REYNOLDS, J. D. FULLMER, and R. G. CRYSTAL. (1978). Bronchoalveolar lavage in interstitial lung disease. Ann. Int. Med. 89:459-466.
7. 7. MARTIN, W. J., J. E. GADEK, G. W. HUNNINGHAKE, et al. 1981. Oxidant injury of lung parenchymal cells. J. Clin. Invest. 68:1277-1288.
8. 8. HUNNINGHAKE, G. W., J. E. GADEK, O. KAWANAMI, V. S. FERRANS, R. J. CRYSTAL. 1979. Inflammatory and immune processes in the human lung in health and disease: Evaluation by bronchoalveolar lavage. Am. J. Pathol. 97:149-206.
9. 9. TURNER-WARWICK, M. and P. L. HASLAM. 1987. The value of serial bronchoalveolar lavage in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am. Rev. Respir. Dis. 135:26-34.
10. 10. SNIDER, G., B. R. CELLI, R. H. GOLDSTEIN, J. J. O'BRIEN, and E. C. LUCEY. 1978. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Am. Rev. Respir. Dis. 117:289-297.
11. 11. WHITE, D. A., M. G. KRIS, and D. E. STOVER. 1987. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax 42:551-552.
12. 12. THRALL, R. S., R. W. BARTON, D'AMATO, and S. B. SULAVIK. 1982. Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induced pulmonary fibrosis in the rat. Am. Rev. Respir. Dis. 126:488-492.
13. 13. HUNNINGHAKE, G. W., J. E. GADEK, H. M. FALES, and R. G. CRYSTAL. 1980. Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization. J. Clin. Invest. 66:473-483.
14. 14. ZHANG, Y., T. C. LEE, and B. GUILLEMIN. 1993. Enhanced IL-1β and TNF-α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol. 150:4188-4196.
15. 15. VANHEE, D., P. GOSSET, and B. WALLERT. 1994. Mechanisms of fibrosis in coal workers pneumoconiosis: increased production of platelet-derived growth factor, insulin-like growth factor type I and transforming growth factor-β and relationship to disease severity. Am. J. Respir. Crit. Care Med. 150:1049-1055.
16. 16. SHAW, R. J., S. H. BENEDICT, and R. A. F. CLARK. 1991. Pathogenesis of pulmonary fibrosis in interstitial lung disease: alveolar macrophage PDGF (β) gene activation and up-regulation by interferon gamma. Am. Rev. Respir. Dis. 143:163-173.
17. 17. KHALIL, N. and R. O'CONNOR. 1995. Cytokine regulation of pulmonary fibrosis: Transforming growth factor-β. In: Pulmonary fibrosis. S. M. Phan, R. S. Thrall, editors. Marcel Dekker, Inc., New York. 80:627-641.
18. 18. KHALIL, N., O. BERENZAY, M. B. SPORN, and A. H. GREENBERG. 1989. Macrophage production of transforming growth factor-β and fibroblast collagen synthesis in chronic pulmonary inflammation. J. Exp. Med. 170:727-737.
19. 19. KHALIL, N., S. CORNE, C. WHITMAN, and H. YACYSHYN. 1996. Plasmin regulates the activation of cell-associated TGF-β secreted by rat alveolar macrophages after in vivo bleomycin injury. Am. J. Respir. Cell Mol. Biol. 15:252-259.
20. 20. IGNOTZ, R. A. and J. MASSAGUE. 1986. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into extracellular matrix. J. Biol. Chem. 261:4335-4345.
21. 21. IYER, S. N., J. S. WILD, M. J. SCHIEDT, D. M. HYDE, S. B. MARGOLIN, and S. N. GIRI. 1995. Dietary intake of pirfenidone ameliorates bleomycin induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125:779-785.
22. 22. IYER, S. N., S. B. MARGOLIN, D. M. HYDE, and S. N. GIRI. 1998. Lung Fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three dose bleomycin hamster model. Exp. Lung. Res. 24:119-132.
23. 23. IYER, S. N., G. GURUJEYALAKSHMI, and S. N. GIRI. 1999. Downregulation of procollagen genes at the transcriptional level in the bleomycin-induced model of lung fibrosis. J. Pharm. Exp. Ther. 289:211-218.
24. 24. WILCOX, M. L., A. KERVITSKY, L. C. WATTERS, and T. E. KING. 1988. Quantification of cells recovered from bronchoalveolar lavage : comparison of cytocentrifuge preparations with the filter method. Am. Rev. Respir. Dis. 158:74-80.
25. 25. LOWRY, O. H., N. J. ROSEBROUGH, A. L. FARR, and R. J. RANDALL. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
26. 26. CRYSTAL, R. G., P. B. BITTERMAN, S. I. RENNARD, A. J. HANCE, and B. A. KEOGH. 1984. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). New Engl. J. Med. 310:154-166.
27. 27. GIRI, S. N. and Q. WANG. 1995. Miscellaneous mediators systems. In: Pulmonary fibrosis. S. M. Phan, R. S. Thrall, editors. Marcel Dekker, Inc., New York. 80:777-836.
28. 28. SMITH, R. E., R. M. STRIETER, S. M. PHAN, et al. 1996. C-C Chemokines: Novel mediators of the profibrotic inflammatory response to bleomycin challenge. Am. J. Respir. Cell Mol. Biol. 15:693-702.
29. 29. GIRI, S. N., M. A. HOLLINGER, and M. J. SCHIEDT. 1981. The effects of paraquat and superoxide dismutase on pulmonary vascular permeability and edema in mice. Arch. Environ. Health 36:149-154.
30. 30. ASO, Y., K. YONEDA, and Y. KIKKAWA. 1976. Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice. Lab. Invest. 35:558-568.
31. 31. WITSCHI, H. P., W. M. HASCHEK, A. J. P. KLIEN-SZANTO, and P. J. HAKKINEN. 1981. Potentiation of diffuse lung damage by oxygen: determining variables. Am. Rev. Respir. Dis. 123:98-103.
32. 32. HASCHEK, W. M. and H. P. WITSCHI. 1979. Pulmonary fibrosis: a possible mechanism. Toxicol. Appl. Pharmacol. 51:475-487.
33. 33. BRIELAND, J. K. and J. C. FANTONE. 1995. Neutrophils and pulmonary fibrosis. In: Pulmonary fibrosis. S. M. Phan, R. S. Thrall, editors. Marcel Dekker, Inc., New York 80:383-397.
34. 34. WEISS, S. J. 1989. Tissue destruction of Neutrophils. New. Engl. J. Med. 320:365-376.
35. 35. KLEBANOFF, S. J. 1988. Phagocytic cells: products of oxygen metabolism. Basic principles and clinical correlates. In: Inflammation. J. I. Gallin, I. M. Goldstein, R. Snyderman, editors. Raven Press, New York. 391-444.
36. 36. KANEKO, M., H. INOUE, R. NAKAZAWA, N. AZUMA, M. SUZUKI, S. YAMAUCHI, and S. B. MARGOLIN. 1988. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin. Exp. Immunol. 113:72-76.
37. 2 integrins in vivo. Proc. Natl. Acad. Sci. 88:7538-7542.
38. 38. GIRI, S. N., S. L. LEONARD, X. SHI, S. B. MARGOLIN, and V. VALEYATHAN. 1999. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. 18:169-177.
39. 39. CASPARY, W. J., D. A. LANZO, and C. NIZIAK. 1982. Effect of deoxyribonucleic acid on the production of reduced oxygen by bleomycin and iron. Biochemistry 21:334-338.
40. 40. SUIGURA, Y. and T. KIKUCHI. 1978. Formation of superoxide and hydroxy radicals in iron (II)-bleomycin oxygen system: electron spin resonance detection by spin trapping. J. Antibiot. 31:1310-1312.
41. 41. KHALIL, N., C. WHITMAN, Z. LI, D. DANIELPOUR, and A. GREENBERG. 1993. Regulation of alveolar-macrophage TGF-β secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J. Clin. Invest. 92:1812-1818.
42. 42. KHALIL, N., R. N. O'CONNOR, M. W. UNRUH, P. W. WARREN, K. C. FLANDER, A. KEMP, O. H. BERENZAY, and A. H. GREENBERG. 1991. Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am. J. Resp. Cell Mol. Biol. 5:155-162.
43. 43. BROCKELMANN, T. J., A. H. LIMPER, T. V. COLBY, and J. A. MCDONALD. 1991. Transforming growth factor β is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl Acad. Sci. U.S.A. 88:6642-6646.
44. 44. WAHL, S. M., D. A. HUNT, L. M. WAKEFIELD, N. MCCARTNEY-FRANCIS, L. M. WAHL, and A. B. ROBERTS. 1987. Transforming growth factor β induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. U.S.A. 84:5788-5792.
45. 45. POSTLEWAITE, A. E., J. KESKI-OJA, H. L. MOSES, and A. J. KING. 1987. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J. Exp. Med. 165:251-256.
46. 46. RAGHOW, R., S. LURIE, J. M. SEYER, and A. H. KANG. 1985. Profiles of steady state levels of mRNAs coding for type I procollagen, elastin and fibronectin in hamster lungs undergoing bleomycin-induced interstitial pulmonary fibrosis. J. Clin. Invest. 76:1733-1739.
47. 47. FINE, A. and R. H. GOLDSTEIN. 1987. The effect of TGF-β on cell proliferation and collagen by fibroblasts. J. Biol. Chem. 262:3897-3902.
48. 48. SPORN, M. B., A. B. ROBERTS, L. M. WAKEFIELD, and B. CROMBRUGGHE. 1987. Some recent advances in the chemistry and biology of transforming growth factor β. J. Cell Bio. 105:1039-1045.
49. 49. GIRI, S. N., D. M. HYDE, and M. A. HOLLINGER. 1993. Effect of antibody to TGF-β on bleomycin induced accumulation of lung collagen in mice. Thorax 48:959-966.
50. 50. CHANDLER, D. B., D. M. HYDE, and S. N. GIRI. 1983. Morphometric estimates of cellular changes during the development of bleomycin-induced lung fibrosis in hamsters. Am. J. Pathol. 112:170-177.
51. 51. THRALL, R. S. and R. W. BARTON. 1984. A comparison of lymphocytes population in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis. Am. Rev. Respir. Dis. 129:279-283.
52. 52. KRAVIS, T. C., A. AHMED, T. E. BROWN, and J. D. FULMER. 1976. Pathogenic mechanism in pulmonary fibrosis. Collagen-induced migration inhibition factor production and cytotoxicity mediated by lymhocytes. J. Clin. Invest. 58:1223-1232.
53. 53. WESTERMANN, W., R. SCHOBAL, E. B. REIBER, and K. H. FRANK. 1999. Th2 cells as effectors in postirradiation pulmonary damage preceding fibrosis in the rat. Int. J. Radiat. Biol. 5:629-638.